Video:
FDA Class I Recall: Abiomed Impella Purge Cassettes Removed Over Risk of Pump Failure and Patient Harm

The U.S. Food and Drug Administration updated this safety communication on April 3, 2026 to state that Abiomed’s removal of certain Impella Purge Cassettes and Impella RP Pump Sets has been classified as a Class I recall, the FDA’s most serious recall type. The FDA says the affected products and recommended actions did not change from the earlier notice, but the classification means continued use of the affected devices may cause serious injury or death.

This development matters because the purge cassette is not a secondary accessory. FDA explains that it delivers rinsing fluid through the Impella catheter to the microaxial blood pump, helping prevent blood from entering the motor. When that process is disrupted, the performance of the system itself may be compromised. In facilities that use Impella systems for circulatory support, the recall therefore creates both a patient safety issue and an immediate inventory control issue.

For hospitals and procedural supply teams, this is the kind of event that tests response speed. Once a Class I recall is posted, facilities are expected to quickly determine whether affected stock is on hand, where it is located, whether it has already been distributed internally, and what replacement pathway is available. FDA’s recall database also notes that posting dates reflect FDA classification dates and do not always mean the action itself is brand new, which is important when tracking recall timing inside a reporting window like March 31 through April 6.

According to the FDA communication, Abiomed notified affected customers that certain Impella Purge Cassettes and Impella RP Pump Sets should be removed from where they are used or sold. The affected devices listed on the FDA page include the Impella RP US Pump Set and the Purge Cassette, 5 Pack. The page also includes product identifiers for these devices, including product codes and UDI-DI entries.

The communication specifically focuses on Generation 1 Purge Cassettes. FDA states that Abiomed is removing Generation 1 units in markets where updated Generation 2 Purge Cassettes are available. That distinction is operationally important because it means facilities are not just removing stock; they are also expected to transition to a replacement version where supply is available.

The FDA instructs users to identify and remove all Generation 1 Purge Cassettes from use. That is the central action in the notice and should be treated as an immediate requirement for any organization storing or using the affected products.

FDA says Abiomed sent affected customers a letter on February 18, 2026 recommending several actions. Facilities were told to review all purge cassettes in inventory, including cassettes packaged individually and cassettes included within Impella RP Pump Sets. If impacted units are found, they should be set aside and quarantined. Customers were also told to use the return shipment label provided by Abiomed to begin the return process.

The notice also addresses continuity of care. FDA states that customers should order Generation 2 Purge Cassettes through their standard process. If a Generation 2 cassette is not available and use of a Generation 1 cassette is absolutely necessary, the user may continue to use it only with increased monitoring of the Purge System and by referring to the instructions for use if a “Purge Pressure Low” alarm appears.

In addition, FDA says the notice should be forwarded to anyone in the facility who manages, transports, stores, stocks, or uses the affected products. If the products were sent to another site, that site should also be informed. Facilities were also advised to post a copy of the notice in a visible area. These directions show that the recall is not only a clinical advisory but also an internal communication and logistics exercise.

FDA states that Abiomed reported Generation 1 Purge Cassettes have an increased risk of purge leaks. If a purge leak occurs and is not addressed, the user may experience low purge pressure. The agency says this can allow biomaterial ingress, which may then lead to an unexpected pump stop.

That sequence is what elevates the seriousness of the event. FDA explains that a pump stop may result in a loss of hemodynamic support and may lead to patient death. Because the Impella system is used in patients needing mechanical circulatory support, this is not a minor performance issue. It is a high-risk failure scenario in a procedure-critical support system.

The FDA page reports that, as of February 3, 2026, Abiomed had reported four serious injuries and no deaths associated with the issue. That incident count gives additional context, but the Class I designation makes clear that the potential severity of harm is the central reason for the agency’s classification.

FDA explains that the purge cassette delivers rinsing fluid to the Impella catheter, and that the purge fluid then flows to the microaxial blood pump to prevent blood from entering the motor. This means the cassette is directly tied to safe device function. A failure affecting purge delivery or pressure can therefore compromise the operation of the system as a whole.

Because the purge cassette is essential to system performance, the recall reaches beyond bedside clinicians. It affects materials management teams, cath lab leadership, inventory coordinators, and supply chain staff responsible for procedure-ready products. In practice, a recall like this requires a coordinated response between clinical engineering, purchasing, procedural leadership, and frontline users. That type of cross-functional visibility is consistent with what hospital supply leaders told Becker’s they want most: stronger supplier coordination, better utilization insight, and tighter case-level supply visibility.

Although the recalled item is tied most directly to cardiovascular support rather than general OR instrumentation, it still has clear implications for the broader U.S. surgical and procedural supply chain. FDA’s recall database explains that classification and posting timing are part of the agency’s formal enforcement process, and once a high-risk classification appears, providers must shift from passive awareness to active inventory action.

This is where the market impact becomes clearer. Becker’s reported on April 2 that hospital supply chain leaders want stronger supplier integration, more transparency, and better SKU-level visibility into utilization and case cost. A Class I recall involving a procedure-critical device component highlights exactly why those capabilities matter. Organizations that can quickly identify affected stock, quarantine it, communicate across departments, and secure replacements are better positioned to avoid care disruption.

For providers, this means recall readiness is becoming part of operational performance. For manufacturers and distributors, it means customers increasingly value traceability, field-action responsiveness, and dependable replacement fulfillment alongside price. In that sense, this recall is not just a safety story. It is also a reminder that supply resilience and device oversight are now central competitive issues in the U.S. procedural market.

FDA states that U.S. customers with adverse reactions, quality problems, or questions about this issue should contact Abiomed using the field action contact information listed on the agency page. The agency also instructs healthcare professionals and consumers to report adverse reactions or quality problems through MedWatch, the FDA Safety Information and Adverse Event Reporting Program.

FDA’s page includes a short timeline for the communication. On February 25, 2026, the agency issued an Early Alert to notify the public of a potentially high-risk device issue. On April 3, 2026, the FDA updated the communication to inform the public that the issue had been classified as a Class I Recall. The content on the page is marked current as of April 3, 2026.

Hospitals, cath labs, and inventory managers should immediately review all Impella purge cassette stock, including units packaged inside affected pump sets. Any Generation 1 Purge Cassettes should be identified, removed from active use, and quarantined. Facilities should also confirm replacement availability and ensure that all departments handling or using the devices have received the recall notice.

— Stat Surgical Supply Team